Beverly Paperiello Email

SVP Program Strategy & Chief Medical Officer . Immunovant

New York, NY

Location

LinkedIn

Current Roles

Employees:
248
Revenue:
$16.9M
About
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Our investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection. We have initiated Phase 2 studies in two target indications: myasthenia gravis (MG) and Gravesᅢᄁ¬ツᆲ¬トᄁ ophthalmopathy (GO). We anticipate that we will submit an IND in one additional indication, warm autoimmune hemolytic anemia (WAIHA), in the second half of 2019. We plan to continue expanding our pipeline with innovative therapies that could transform the lives of patients living with autoimmune diseases. *Please note that all applications should be placed through our official career site: https://lnkd.in/gyVgXhZ We will never email you to ask for personal information such as SSN or banking information nor would we ever ask a candidate for payment of any kind as part of the hiring or onboarding process.
Immunovant Address
320 W 37th St
New York, NY
United States
Immunovant Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.